

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application No.	10/549,384
Filing Date	November 3, 2005
First Named Inventor	Paul Leonard Greenhaff
Art Unit	1623
Examiner Name	Ganapathy Krishnan
Attorney Docket Number	27053-17244 US (formerly SWIN.3306)

Sheet

1

of

2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document No. Number – Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US-		
		US-		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ – Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	C1	BRASS, E., et al., "Effect of intravenous L-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans," Clinical Pharmacology & Therapeutics, June 1994, Pages 681-692.	
	C2	BRASS, E., "Supplemental carnitine and exercise ¹⁻³ ," The American Journal of Clinical Nutrition, 2000, Pages 618S-23S, Vol. 72.	
	C3	CEDERBLAD, G., et al., "A Method for the Determination of Carnitine in the Picomole Range," Clinica Chimica Acta, 1972, Pages 235-243, Vol. 37.	
	C4	DECOMBAZ, J., et al., "Effect of L-carnitine on submaximal exercise metabolism after depletion of muscle glycogen," Medicine and Science in Sports and Exercise, 1992, pages 733-740.	
	C5	GEORGES, B., et al., "Carnitine Transport into Muscular Cells. Inhibition of Transport and Cell Growth by Mildronate," Biochemical Pharmacology, 2000, Vol. 59, pp. 1357-1363.	
	C6	GREIG, C., et al., "The effect of oral supplementation with L-carnitine on maximum and submaximum exercise capacity," European Journal of Applied Physiology and Occupational Physiology, 1987, Pages 457-460, Vol. 56.	
	C7	HARPER, P., et al., "Pharmacokinetics of Intravenous and Oral Bolus Doses of L-Carnitine in Healthy Subjects," European Journal of Clinical Pharmacology, 1988, Pages 555-562, Vol. 35.	
	C8	MARCONI, C., et al., "Effects of L-carnitine loading on the aerobic and anaerobic performance of endurance athletes," European Journal of Applied Physiology and Occupational Physiology, 1985, Pages 131-135, Vol. 54.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Applicant's unique citation designation number (optional). 2See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application No.	10/549,384
Filing Date	November 3, 2005
First Named Inventor	Paul Leonard Greenhaff
Art Unit	1623
Examiner Name	Ganapathy Krishnan
Attorney Docket Number	27053-17244 US (formerly SWIN.3306)

Sheet

2

of

2

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	C9	OYONO-ENGUELLE, S., et al., "Prolonged submaximal exercise and L-carnitine in humans," European Journal of Applied Physiology and Occupational Physiology, 1988, Pages 53-61, Vol. 58.	
	C10	REBOUCHE, C., et al., "Renal adaptation to dietary carnitine in humans ¹⁻³ ," American Journal Clinical Nutrition, 1993, Vol. 58, Pages 660-665.	
	C11	REBOUCHE, C., "Carnitine function and requirements during the life cycle," The FASEB Journal, December 1992, Pages 3379-3386, Vol. 6.	
	C12	REBOUCHE, C., et al., "Metabolic Fate of Dietary Carnitine in Human Adults: Identification and Quantification of Urinary and Fecal Metabolites," Metabolism and Hormonal Regulation, The Journal of Nutrition, October 13, 2010, Pages 539-546.	
	C13	SEGRE, G., et al., "Plasma and Urine Pharmacokinetics of Free and of Short-chain Carnitine after Administration of Carnitine in Man," Drug Research, 1988, Pages 1830-1834, Vol. 38, No. 12.	
	C14	SOOP, M., et al., "Influence of carnitine supplementation on muscle substrate and carnitine metabolism during exercise," The American Physiological Society, 1988, Pages 2394-2399.	
	C15	STADLER, D., et al., "Effect of dietary macronutrient content on carnitine excretion and efficiency of carnitine reabsorption ¹⁻³ ," The American Journal of Clinical Nutrition, 1993, Vol. 58, Pages 868-872.	
	C16	TAYLOR, P., "Absorbing competition for carnitine," Perspectives, Journal of Physiology, 2001, Page 283, Vol. 532, No. 2.	
	C17	VAN LOON, L., et al., "The effects of increasing exercise intensity on muscle fuel utilization in humans," Journal of Physiology, 2001, Pages 295-304, Vol. 536, No. 1.	
	C18	VECCHIET, L., et al., "Influence of L-carnitine administration on maximal physical exercise," European Journal of Applied Physiology and Occupational Physiology, 1990, pages 486-490, vol. 61.	
	C19	VUKOVICH, M., et al., "Carnitine supplementation: effect on muscle carnitine and glycogen content during exercise," Medicine and Science in Sports and Exercise, 1994, Pages 1122-1129.	
	C20	WYSS, V., et al., "Effects of L-carnitine administration in V _{O2max} and the aerobic-anaerobic threshold in normoxia and acute hypoxia," European Journal of Applied Physiology and Occupational Physiology, 1990, Pages 1-6.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Applicant's unique citation designation number (optional). 2See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.